Home » Stocks » PTI

Proteostasis Therapeutics, Inc. (PTI)

Stock Price: $1.09 USD 0.04 (3.81%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $1.07 -0.02 (-1.84%) Nov 27, 2:24 PM

Stock Price Chart

Key Info

Market Cap 56.88M
Revenue (ttm) n/a
Net Income (ttm) -38.80M
Shares Out 52.18M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $1.09
Previous Close $1.05
Change ($) 0.04
Change (%) 3.81%
Day's Open 1.03
Day's Range 1.03 - 1.11
Day's Volume 385,773
52-Week Range 0.87 - 4.72

More Stats

Market Cap 56.88M
Enterprise Value 15.67M
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 52.18M
Float 43.73M
EPS (basic) -0.75
EPS (diluted) -0.75
FCF / Share -0.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.40M
Short Ratio 3.18
Short % of Float 3.20%
Beta 1.19
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.48
Revenue n/a
Operating Income -39.39M
Net Income -38.80M
Free Cash Flow -40.84M
Net Cash 41.21M
Net Cash / Share 0.79
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -31.16%
ROE -72.38%
ROIC -146.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(175.23% upside)
Current: $1.09
Target: 3.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth76.06%-46.83%-36.3%94.43%-16.27%351.36%-
Gross Profit5.002.845.348.384.315.151.14
Operating Income-61.15-63.18-59.97-37.46-24.53-15.68-15.58
Net Income-59.13-61.83-59.43-37.23-25.04-15.77-15.72
Shares Outstanding51.1438.5025.4118.760.550.470.42
Earnings Per Share-1.16-1.61-2.34-2.06-42.14-63.74-53.87
Operating Cash Flow-53.22-58.84-52.40-41.93-19.42-8.66-12.91
Capital Expenditures-0.01-0.42-0.12-0.22-0.26-0.17-0.04
Free Cash Flow-53.23-59.26-52.51-42.14-19.68-8.83-12.96
Cash & Equivalents70.3011874.7685.8014.149.092.89
Total Debt-----10.20-
Net Cash / Debt70.3011874.7685.8014.14-1.112.89
Book Value62.3811468.8181.46-108-95.08-73.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Proteostasis Therapeutics, Inc.
Country United States
Employees 44
CEO Meenu Chhabra Karson

Stock Information

Ticker Symbol PTI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTI
IPO Date February 11, 2016


Proteostasis Therapeutics, a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.